| Abstract: |
Introduction: Urothelial cancer (UC) remains a significant public health problem, with no new second-line agents FDA-approved in the US. Next-generation sequencing technologies are starting to generate a molecular landscape of UC thus revealing novel molecular targets. Areas covered: In this review, the authors provide a detailed review of novel molecular targets in UC based on published genomic analyses of urothelial tumors. We provide an overview of each molecular target with a brief discussion of therapeutic strategies and clinical trials targeting each pathway. Expert opinion: UC continues to be a lethal disease with no FDA-approved effective second-line therapies. Platinum resistance continues to be a daunting clinical problem. Next-generation sequencing methods have led to the elucidation of numerous molecular targets in UC, including PI3K, to the elucidation of numerous molecular targets in UC, including PI3K, ERBB2 and FGFR3, among many others. These molecular perturbations can be exploited therapeutically with targeted therapies in patient populations enriched for these molecular alterations, thus paving the way for precision medicine in UC management. © 2015 Informa UK, Ltd. All rights reserved. |
| Keywords: |
protein kinase b; protein phosphorylation; gene mutation; review; cisplatin; nonhuman; drug targeting; ipilimumab; cancer immunotherapy; epidermal growth factor receptor; epidermal growth factor receptor 2; antineoplastic activity; cetuximab; fibroblast growth factor receptor 3; mammalian target of rapamycin; tuberin; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; gefitinib; urothelial carcinoma; vorinostat; genomics; 5 aza 2' deoxycytidine; targeted therapy; heat shock protein 27; trastuzumab; cytotoxic t lymphocyte antigen 4; transitional cell carcinoma; everolimus; lapatinib; chromatin assembly and disassembly; enzyme active site; phase 2 clinical trial (topic); phase 1 clinical trial (topic); molecular targets; mpdl 3280a; dovitinib; buparlisib; human; 3 (2,6 dichloro 3,5 dimethoxyphenyl) 1 [6 [[4 (4 ethyl 1 piperazinyl)phenyl]amino] 4 pyrimidinyl] 1 methylurea; 3,3',4',5 tetrahydroxy 6,7 dimethoxyflavone; apatorsen; omipalisib
|
